Oxprenolol in the treatment of migraine.

Thirty migraine patients received oxprenolol (Trasicor), which is an adrenergic beta-receptor blocking agent with weak beta-stimulating intrinsic activity. The dosage was 80 mg three times a day. The treatment was given by a double blind cross-over technique in which the effect was compared with placebo. Each compound was administered for 8 weeks with an intermediate week without medication (wash-out). Oxprenolol had no significant effects in the prevention of migraine attacks. Our study lends further support to the assumption that differences may exist between different beta-receptor blocking agents in their effectiveness in migraine prophylaxis.